This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

       

Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.

Continue

Cancel

Popup

Order GSK Vaccines

Vaccine Patient Assistance

Coding for GSK Vaccines

Register for Product Updates

THE IMPACT OF MENINGOCOCCAL DISEASE IN YOUR AREA

Meningococcal disease (MenB) is uncommon but potentially deadly, and has national impact.9 The map below details cases of all serogroups from 2014-2017. To see cases by state, click that state on the map, or choose State View.

Total Meningococcal Disease Cases in the US, 2014-2017 including all serogroups & unknown.
Source: Nationally Notifiable Disease Surveillance System.
STATE

To see cases in a different state, choose another from the dropdown menu.

STATE
Total Meningococcal Disease Cases in , 2014-2017 including all serogroups & unknown.
Source: Nationally Notifiable Disease Surveillance System.

Quick Facts About MenB

  • Serogroup B caused over 60% of all US meningococcal disease cases in patients aged 16-23 years, from 2015 to 2017; N=18815 LEARN MORE
  • To help protect against the 5 most common vaccine-preventable serogroups, 2 different types of vaccines are needed—one for MenACWY, and one for MenB11 Vaccination may not protect all recipients.

MenB NEWS in the US

New York, Syracuse University Case: October 2018

Syracuse, NY: A Syracuse University student was diagnosed with meningitis, and the serogroup was later confirmed to be of type B. The student was moved off campus to a hospital near their hometown. All those living in close proximity to the student were notified and given antibiotics according to public health protocols.

Source(s):

https://www.thenewshouse.com/campus-news/syracuse-university-reports-a-single-case-of-meningitis/. Updated October 5, 2018. Accessed October 8, 2018.
California, San Diego State University Outbreak: September 28, 2018

San Diego, CA: A meningitis outbreak has been declared after 3 students were diagnosed with the disease. All 3 cases occurred within a 3.5-month period and were caused by serogroup B. The San Diego County Public Health Services has highly recommended that all undergraduate students younger than 24 years of age, who have not been immunized against meningococcus B (MenB), receive a MenB vaccination.

Source(s):

http://newscenter.sdsu.edu/sdsu_newscenter/news_story.aspx?sid=77389. September 28, 2018. Accessed October 8, 2018.
Indiana, Purdue University Vaccination Requirement

Beginning in fall of 2018, Purdue University will require incoming students aged 23 and younger to complete a MenB vaccination series prior to matriculation.

Source(s):

https://www.purdue.edu/push/Immunization/

http://wjts.tv/2018/05/purdue-university-and-indiana-university-require-incoming-students-to-receive-additional-meningitis-vaccination/
Indiana, Indiana State University Vaccination Requirement

Beginning in fall of 2018, Indiana State University (all campuses) will require all incoming students aged 24 and younger (as of August 1, 2018) who are enrolled in at least one on-campus course and/or are living in an Indiana State residence hall or apartment, to complete a MenB vaccination series prior to matriculation.

Source(s):

https://www.indstate.edu/sites/default/files/media/documents/pdf/immunizationflyer.pdf

https://www.indstate.edu/registrar/state-immunization-requirements
Indiana, Ball State University Vaccination Requirement

Effective July 1, 2018, Ball State University will require all domestic students 23 years of age and younger to provide proof of MenB vaccination (2 or more doses).

Source(s):

https://www.bsu.edu/campuslife/healthcenter/admreq

http://www.ballstatedaily.com/article/2018/05/news-meningitis
Indiana, Manchester University Vaccination Requirement

Manchester University will require students 23 years old and younger to provide proof of MenB vaccination.

Source(s):

https://www.manchester.edu/docs/default-source/academics/mat/health_history_form_000.pdf?sfvrsn=2

https://indianapublicmedia.org/news/indiana-law-requires-student-vaccinations-meningitis-strain-147211/
Indiana, Marian University Vaccination Requirement

Marian University requires MenB vaccination for all students.

Source(s):

https://marian.edu/campus-life/health-and-wellness/immunization-requirements

https://indianapublicmedia.org/news/indiana-law-requires-student-vaccinations-meningitis-strain-147211/
Indiana, Rose-Hulman Institute of Technology Vaccination Requirement

In accordance with state law, Rose-Hulman Institute of Technology requires students to provide proof of MenB vaccination.

Source(s):

https://www.rose-hulman.edu/campus-life/student-services/wellness-and-health-services/health-services/index.html
Indiana, University of Indianapolis Vaccination Requirement

The University of Indianapolis requires students 23 years of age or younger to provide proof of 2 or more MenB vaccinations.

Source(s):

http://health.iupui.edu/docs/IU_HPP_Immunization.pdf

https://www.uindy.edu/documents/1-17_SHR.pdf
Massachussets, Smith College Vaccination Requirement

Smith College requires 2 or more doses of a MenB vaccine for all entering students.

Source(s):

https://www.smith.edu/sites/default/files/media/Documents/Health-Wellness/HealthForms2018R4.pdf
New Hampshire, New England College Vaccination Requirement

New England College will require proof of 2 doses of MenB vaccination by August 1 (on an annual basis) for all undergraduate and international students.

Source(s):

https://www.nec.edu/students-faculty-staff/health-wellness/
Indiana, Indiana University MenB Vaccination Requirement: Fall 2018

Starting fall 2018, first-year students aged 23 or younger will have to be immunized with two doses of MenB.

Source(s):

https://studentcentral.indiana.edu/personal-information/immunizations.html
Indiana, MenB Vaccination Recommendation: Fall 2018

According to the Indiana State Department of Heath Immunization Program, two doses of MenB vaccine are recommended for students in the 12th grade enrolled in high school.

Source(s):

http://www.vaccinateindiana.org/vaccineschedules/
Northampton, Massachusetts, Smith College Case: February 2018

The Centers for Disease Control and Prevention confirmed that a Smith student hospitalized with bacterial meningitis was infected with serogroup B. While it is the same meningitis serogroup as last fall's outbreak at the University of Massachusetts Amherst, it is not known whether the cases are related.

Source(s):

https://www.smith.edu/news/meningitis-update-student-vaccination-clinic-thursday-march-1/
Oregon, Oregon State University New MenB Vaccination Requirement: December 2017

Corvallis: Oregon State University will require all Corvallis students aged 25 and under to be vaccinated for meningococcal B disease by February 15, 2018.

This new requirement results from a sixth case of an undergraduate student with presumed meningococcal B disease over the previous year.

Source(s):

http://international.oregonstate.edu/translated-announcements/12202017-new-osu-meningitis-b-vaccination-requirement
Massachusetts, UMass Amherst Outbreak: November 2017

Amherst, MA: December 5, 2017: An outbreak of meningitis was reported on November 16 at UMass Amherst. Two students were confirmed to have been diagnosed with meningococcal disease in October and November.

The Centers for Disease Control and Prevention (CDC) were involved in conducting the testing of the two students. The situation has been classified an outbreak because the two students infected contracted the same strain of serogroup B meningitis.

The classification of an outbreak means there is increased risk of contracting the disease both on- and off-campus. UMass has recommended the serogroup B meningococcal vaccine for all of its undergraduate students. Likewise, Amherst College Health Services has strongly recommended the serogroup B meningococcal vaccine for all Amherst College students who take classes or spend considerable time at UMass. The meningococcal vaccine required of all students before entering Amherst does not protect against this particular strain of meningitis.

Source(s):

http://amherststudent.amherst.edu/?q=article/2017/12/05/umass-meningitis-outbreak-prompts-concern
Massachusetts, UMass Amherst Case: November 2017

Amherst, MA: November 15, 2017: A male undergraduate student was diagnosed with MenB, as reported on the Amherst Wire website.

Source(s):

https://amherstwire.com/22204/campus/second-case-of-meningococcal-disease-diagnosed-at-umass/
Oregon, Oregon State University Outbreak: March 2017

Corvallis, OR: Three cases of an OSU Corvallis student being diagnosed with meningococcal B disease occurred within four months, prompting the university to recommend that students at the highest risk receive meningococcal B vaccinations.

Following the protocols of the Centers for Disease Control and Prevention, the university is recommending meningococcal B vaccinations for all Oregon State undergraduate students aged 25 or younger. In particular, OSU students aged 25 or younger and who live in on-campus housing or who are members of— or who visit— fraternal living groups associated with the university are urged to act on this recommendation.

Source(s):

https://oregonstate.edu/alert/meningitis
Madison, WI, University of Wisconsin—Madison Case: October 2016

On October 27, 2016, a third case of meningococcal disease was confirmed on the UW— Madison campus. Students at increased risk were notified of the case and all UW— Madison undergraduate students aged 25 and younger were strongly urged to get vaccinated against the disease for free at University Health Services.

Source(s):

https://news.wisc.edu/uw-madison-identifies-possible-third-case-of-meningococcal-disease-free-vaccine-today-for-undergraduates/
Wisconsin, University of Wisconsin—Madison Outbreak: October 2016

Madison, WI: Three UW— Madison students were diagnosed with meningitis.  All three cases were the same strain of meningococcal disease serogroup B even though the students appeared to have no connections to each other. By the standards of the Centers for Disease Control and Prevention, these cases constituted an outbreak.  After the second confirmed case, the campus launched a comprehensive public health and media campaign to increase awareness about meningitis B symptoms, limit the spread of the illness, and publicize the availability of a vaccine to students.

Source(s):

www.uhs.wisc.edu/news/end-of-outbreak/
Wisconsin, University of Wisconsin—Madison Case: October 2016

October 7, 2016: Two UW— Madison, Wisconsin students were hospitalized with confirmed cases of meningococcal disease with one being meningococcal serogroup B disease. At the time of diagnosis, both students were recovering.

Source(s):

https://news.wisc.edu/uw-madison-students-hospitalized-with-meningitis/
Pennsylvania, Bucknell University Requires MenB Vaccination

All enrolling Bucknell students are required to be immunized with at least one dose of MenB.

Source(s):

https://www.bucknell.edu/Documents/HealthServices/MedicalRecordForm.pdf
New Jersey, Rutgers University—New Brunswick Outbreak: June 2, 2016

New Brunswick, NJ: June 2, 2016: A match in the strain of bacteria in two students diagnosed with meningitis confirmed that there is an outbreak of this disease at Rutgers University—New Brunswick.

Two students were diagnosed with meningitis caused by Neisseria meningitidis, serogroup B. Special testing performed by the Centers for Disease Control and Prevention (CDC) showed that the bacteria from the two students are genetically indistinguishable (a match). Although no common link has been identified between the two students, the fact that the strains of MenB bacteria in the two students match indicates that the strain is present in the undergraduate population of that university, and that there is an outbreak.

The first student with meningococcal disease was hospitalized on March 18, 2016. The second was hospitalized on April 29. Close contacts of both students were identified and notified to receive prophylactic antibiotics. Both students have recovered.

Source(s):

http://health.rutgers.edu/wp-content/uploads/sites/57/2016/07/Meningococcal-Disease-Rutgers-Fact-Sheet-06-02-2016.pdf
New Haven, Connecticut, Yale University Case: February 2016

The Centers for Disease Control and Prevention confirmed that a Silliman College freshman who was hospitalized for a possible case of bacterial meningitis has the disease. The student tested positive for serogroup B meningococcal disease.

Source(s):

https://yaledailynews.com/blog/2016/02/18/meningitis-confirmed-on-campus/
California, Santa Clara University Outbreak: January 31, 2016

Santa Clara, CA: An outbreak of meningitis at Santa Clara University prompted the administration of 4,923 doses of meningococcal B vaccine— which protects against the serogroup B strain of meningococcal infection— at 4 vaccination clinics on campus this past weekend.

Three Santa Clara University (SCU) students became ill on Sunday January 31st, and were confirmed to be infected with the bacteria Neisseria meningitidis, serogroup B. Two of the ill students developed meningitis as a result of the bacterial infection, while a third developed septicemia (a blood infection). All three students have been discharged from the hospital in good condition.

Source(s):

https://www.scu.edu/news-and-events/feature-stories/stories/meningitis-vaccination-information-for-scu-campus.html
Pennsylvania, Lehigh University Recommends MenB Vaccination: June 2015

Bethlehem, PA: Lehigh University is recommending and offering serogroup B vaccination based on our experience with the illness on our campus and the expectation that the CDC will soon recommend it for college students.

Source(s):

https://studentaffairs.lehigh.edu/sites/studentaffairs.lehigh.edu/files/offices/health/docs/2015MeningitisInfoForm2015.pdf
Oregon, University of Oregon Outbreak: March 2015

Portland, OR: June 2015: Seven cases of serogroup B meningococcal disease occurred at the University of Oregon from January to June 2015. One student died.

Source(s):

http://www.nmaus.org/disease-prevention-information/serogroup-b-meningococcal-disease/outbreaks/
Rhode Island, Providence College Case: February 2015

Providence, RI: February 9, 2015: School officials have announced that there has been a case of meningitis at Providence College. A second case of meningococcal meningitis was confirmed in a Providence College student Sunday as the school unrolled its effort to vaccinate the entire student body. Students began receiving the Serogroup B Meningococcal Vaccine— the first of three rounds of the vaccine they will take over the next six months.

Source(s):

http://www.providencejournal.com/article/20150209/NEWS/150209640
Washington, DC, Georgetown University Case: September 2014

On September 16, 2014, a female student at Georgetown University died from contracting bacterial meningitis. The President for Student Health Services confirmed her case to be meningococcal serogroup B.

Source(s):

http://www.thehoya.com/sophomore-dies-from-meningitis/

http://www.thehoya.com/bacterial-meningitis-confirmed/
Texas State, Meningitis Vaccination Requirement: January 2014

San Marcos, TX: Effective January 1, 2014,  Texas Senate Bill 1107, as amended by Senate Bill 62, requires that students who will be under age 22 on their first day of class at a public, private or independent institution of higher education in Texas, provide proof of immunization for bacterial meningitis. The vaccination or booster dose must have been received during the five years prior to enrollment and at least ten days before the start of classes.

The bill was named after two young adult college students who contracted meningitis serogroup B; one survived, one did not.

Source(s):

http://www.admissions.txstate.edu/meningitis.html

https://capitol.texas.gov/BillLookup/History.aspx?LegSess=82R&Bill=SB1107

https://www.dallasnews.com/life/better-living/2013/08/13/texas-meningitis-survivor-and-activist-jamie-schanbaum-to-be-honored-at-dallas-hadassah-events-aug-25
New Jersey, Princeton University Outbreak: November 2013

Princeton, NJ: November 11, 2013: Between March 2013 and March 2014, nine cases of serogroup B meningococcal disease have been associated with Princeton University. Seven cases involved Princeton University students.

One Drexel University student who was in contact with Princeton students died. Some students are suffering neurological effects such as memory loss, difficulty retaining information and difficulty concentrating.

Source(s):

https://web.princeton.edu/sites/emergency/meningitis/FAQ-Admitted.html Accessed March 27, 2018.

http://www.nmaus.org/disease-prevention-information/serogroup-b-meningococcal-disease/outbreaks/
California, Santa Barbara University Outbreak: December 4, 2013

Santa Barbara, CA: December 4, 2013: A University of California, Santa Barbara student had both of his feet amputated after he contracted meningitis in an outbreak that sickened three other students, school and health officials said.

Aaron Loy, an 18-year-old freshman lacrosse player, had both of his feet amputated when the disease affected the blood supply to his limbs.

He and three other students with meningococcal disease became ill within a three-week time period in November, with Loy's case resulting in permanent disability, the Santa Barbara County Public Health Department said Monday.

Source(s):

https://www.nbclosangeles.com/news/local/uc-santa-barbara-meningitis-outbreak-aaron-loy-234523891.html

http://www.nmaus.org/disease-prevention-information/serogroup-b-meningococcal-disease/outbreaks/
Philadelphia, PA, University of Pennsylvania Cases: March 2009

On March 7, 2009, an undergraduate student at the University of Pennsylvania was hospitalized for a confirmed case of meningococcal serogroup B. The student was in critical condition at the time of diagnosis, but was stable and improving. The student's family was promptly informed by school officials, and the UPenn student body was notified via email soon after. There were two previous MenB cases at UPenn who had no contact with this student.

Source(s):

http://www.thedp.com/article/2009/03/student_hospitalized_with_meningitis_over_break_in_stable_condition_interactive_features
Atlanta, Georgia, Georgia Tech. MenB Vaccination Recommended

Georgia Tech lists MenB as a recommended vaccine, noting that recommendations may change in the event of an outbreak.

Source(s):

https://health.gatech.edu/services/primary/important/meningitis
Nashville, Tennessee, Vanderbilt University. MenB Vaccination Recommended

Vanderbilt University lists MenB as a recommended vaccination for new students.

Source(s):

https://www.vumc.org/student-health/files/student-health/public_files/2017 Vaccine Requirements.pdf
San Marcos, Texas, Texas State University. MenB Vaccination Recommended

Texas State University recommends MenB vaccination for students.

Source(s):

http://www.admissions.txstate.edu/meningitis/faq.html
Arizona, Arizona State University. MenB Vaccine Strongly Recommended

Arizona State University Health Services strongly recommends MenB vaccination for students younger than 24 years of age or living in the residence halls or participating in groups including sports teams, fraternities and sororities, you are strongly recommended to receive the vaccination at the beginning of the semester.

Source(s):

https://eoss.asu.edu/health/resources/healthupdates

References

  1. Prescribing Information for BEXSERO.
  2. Prescribing Information for TRUMENBA.
  3. Wang X, Cohn A, Comanducci M, et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine. 2011;29(29-30):4739-4744.
  4. Bai X, Findlow J, Borrow R. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther. 2011;11(7):969-985.
  5. Ellis TN, Kuehn MJ. Virulence and immunomodulatory roles of bacterial outer membrane vesicles. Microbiol Mol Biol Rev. 2010;74(1):81-94.
  6. Biagini M, Spinsanti M, De Angelis G, et al. Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined. Proc Natl Acad Sci USA. 2016;113(10):2714-2719.
  7. Vogel U, Taha M-K, Vazquez JA, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis. 2013;13(5):416-425.
  8. Data on file, GSK.
  9. Pelton SI. Meningococcal disease awareness: clinical and epidemiological factors affecting prevention and management in adolescents. J Adolesc Health. 2010;46:S9-S15.
  10. MacNeil J, Cohn A. Meningococcal disease. In: Roush SW, Baldy LM, eds. Manual for the Surveillance of Vaccine-Preventable Diseases. 5th ed. Atlanta, GA: Centers for Disease Control and Prevention; 2011. www.cdc.gov/vaccines/pubs/surv-manual/chpt08-mening.pdf. Accessed February 18, 2019.
  11. Meningococcal vaccination: what everyone should know. Centers for Disease Control and Prevention website: https://www.cdc.gov/vaccines/vpd/mening/hcp/adolescent-vaccine.html. Last Update May 19, 2017. Accessed April 25, 2019.
  12. Meningococcal disease. In: Hamborsky J, Kroger A, Wolfe C, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th ed. Washington, DC: Public Health Foundation; 2015:231-245. www.cdc.gov/vaccines/pubs/pinkbook/mening.html. Accessed February 18, 2019.
  13. Slack R, Hawkins KC, Gilhooley L, Addison GM, Lewis MA, Webb NJA. Long-term outcome of meningococcal sepsis-associated acute renal failure. Pediatr Crit Care Med. 2005;6(4):477-479.
  14. Vyse A, Anonychuk A, Jäkel A, Wieffer H, Nadel S. The burden and impact of severe and long-term sequelae of meningococcal disease. Expert Rev Anti Infect Ther. 2013;11(6):597-604.
  15. Centers for Disease Control and Prevention website. Enhanced Meningococcal Disease Surveillance Reports, 2015-2017. www.cdc.gov/meningococcal/surveillance/index.html#enhanced-reports. Updated March 28, 2017. Accessed April 1, 2019.
  16. MacNeil JR, Rubin L, Folaranmi T, Ortega-Sanchez IR, Patel M, Martin SW. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR. 2015;64(41):1171-1176.
MenBMapConfigRecord - qaun-tzce.geojson
MenBMapConfigRecord - gvyj-7z2x.geojson
MenBMapConfigRecord - kdpu-r2df.geojson
MenBMapConfigRecord - b9yw-7xai.geojson

Indication

BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years.

Approval of BEXSERO is based on demonstration of immune response, as measured by serum bactericidal activity against three serogroup B strains representative of prevalent strains in the United States. The effectiveness of BEXSERO against diverse serogroup B strains has not been confirmed.

Important Safety Information for BEXSERO

  • BEXSERO is contraindicated in cases of hypersensitivity, including severe allergic reaction, to any component of the vaccine, or after a previous dose of BEXSERO
  • Appropriate observation and medical treatment should always be readily available in case of an anaphylactic reaction following the administration of the vaccine
  • The tip caps of the prefilled syringes contain natural rubber latex, which may cause allergic reactions
  • Syncope (fainting) can occur in association with administration of BEXSERO. Ensure procedures are in place to avoid injury from falling associated with syncope
  • The most common solicited adverse reactions observed in clinical trials were pain at the injection site (≥83%), myalgia (≥48%), erythema (≥45%), fatigue (≥35%), headache (≥33%), induration (≥28%), nausea (≥18%), and arthralgia (≥13%)
  • Vaccination with BEXSERO may not provide protection against all meningococcal serogroup B strains
  • Some individuals with altered immunocompetence may have reduced immune responses to BEXSERO
  • Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroup B even if they develop antibodies following vaccination with BEXSERO
  • Vaccination with BEXSERO may not result in protection in all vaccine recipients

Please see full Prescribing Information for BEXSERO.

All trademarks are the property of their respective owners.